These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 2452563)

  • 1. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
    Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
    Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
    Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
    Meierhenrich R; Carlsson J; Seifried E; Pfarr E; Smolarz A; Neuhaus KL; Tebbe U
    Int J Cardiol; 1998 Jun; 65(1):57-63. PubMed ID: 9699932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
    Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
    Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR; Lijnen HR; Stassen JM; Collen D
    Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
    Van de Werf F; Nobuhara M; Collen D
    Ann Intern Med; 1986 Mar; 104(3):345-8. PubMed ID: 3080936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
    Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
    Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
    J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
    Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
    Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.